Momentum of hope: The journey toward a universal TB vaccine

In addressing the persistent threat of tuberculosis (TB) - a disease that claims millions of lives, especially in low-income countries - this correspondence underlines the critical role of advancing vaccine research. Historically, the BCG vaccine, developed over a century ago, has been the cornerstone of TB prevention. However, its efficacy is limited, particularly in adults and against pulmonary TB, the most common form of the disease. Recent developments, such as the M72/AS01E vaccine, demonstrate promising results in increasing protection against TB in adults with latent infections. These advancements represent a significant leap forward in the quest to control and eventually eradicate TB. This piece highlights the necessity of continued investment in vaccine research and development. The pursuit of more effective TB vaccines, capable of providing broader protection across all age groups, is paramount. This effort not only aligns with the WHO's End TB Strategy but also offers hope for a future where TB is no longer a global health crisis